Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial
Authors:
- on behalf of the MiTy Collaborative GroupOGon behalf of the MiTy Collaborative Group
- Denice S. FeigDFDenice S. Feig
- Kellie MurphyKMKellie Murphy
- Elizabeth AsztalosElizabeth Asztalos
- George TomlinsonGTGeorge Tomlinson
- Johanna SanchezJSJohanna Sanchez
- Bernard ZinmanBZBernard Zinman
- Arne OhlssonAOArne Ohlsson
- Edmond A. RyanEREdmond A. Ryan
- I. George FantusIFI. George Fantus
- Anthony B. ArmsonAAAnthony B. Armson
- Lorraine L. LipscombeLLLorraine L. Lipscombe
Open Access
- 19 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 16 (1) , 1-8
Abstract
The incidence of type 2 diabetes in pregnancy is rising and rates of serious adverse maternal and fetal outcomes remain high. Metformin is a biguanide that is used as first-line treatment for non-pregnant patients with type 2 diabetes. We hypothesize that metformin use in pregnancy, as an adjunct to insulin, will decrease adverse outcomes by reducing maternal hyperglycemia, maternal insulin doses, maternal weight gain and gestational hypertension/pre-eclampsia. In addition, since metformin crosses the placenta, metformin treatment of the fetus may have a direct beneficial effect on neonatal outcomes. Our aim is to compare the effectiveness of the addition of metformin to insulin, to standard care (insulin plus placebo) in women with type 2 diabetes in pregnancy. The MiTy trial is a multi-centre randomized trial currently enrolling pregnant women with type 2 diabetes, who are on insulin, between the ages of 18–45, with a gestational age of 6 weeks 0 days to 22 weeks 6 days. In this randomized, double-masked, parallel placebo-controlled trial, after giving informed consent, women are randomized to receive either metformin 1,000 mg twice daily or placebo twice daily. A web-based block randomization system is used to assign women to metformin or placebo in a 1:1 ratio, stratified for site and body mass index. The primary outcome is a composite neonatal outcome of pregnancy loss, preterm birth, birth injury, moderate/severe respiratory distress, neonatal hypoglycemia, or neonatal intensive care unit admission longer than 24 h. Secondary outcomes are large for gestational age, cord blood gas pH < 7.0, congenital anomalies, hyperbilirubinemia, sepsis, hyperinsulinemia, shoulder dystocia, fetal fat mass, as well as maternal outcomes: maternal weight gain, maternal insulin doses, maternal glycemic control, maternal hypoglycemia, gestational hypertension, preeclampsia, cesarean section, number of hospitalizations during pregnancy, and duration of hospital stays. The trial aims to enroll 500 participants. The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to insulin in this high risk population. ClinicalTrials.gov Identifier: no. NCT01353391 . Registered February 6, 2009.Keywords
Funding Information
- Canadian institutes for health research CIHR (MOP 106678)
This publication has 34 references indexed in Scilit:
- Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)Diabetes Care, 2011
- Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantageDiabetic Medicine, 2011
- Development and evaluation of a standardized registry for diabetes in pregnancy using data from the Northern, North West and East Anglia regional audits1Diabetic Medicine, 2011
- Diabetes Trends Among Delivery Hospitalizations in the U.S., 1994–2004Diabetes Care, 2010
- Fetuses of Obese Mothers Develop Insulin Resistance in UteroDiabetes Care, 2009
- Trends in prevalence and outcomes of pregnancy in women with pre‐existing type I and type II diabetesBJOG: An International Journal of Obstetrics & Gynaecology, 2008
- Type 2 diabetes and pregnancySeminars in Fetal and Neonatal Medicine, 2005
- A New and Improved Population-Based Canadian Reference for Birth Weight for Gestational AgePediatrics, 2001
- The Neonate With MacrosomiaClinical Obstetrics and Gynecology, 2000
- Anthropometric estimation of neonatal body compositionAmerican Journal of Obstetrics and Gynecology, 1995